BioPharma Resources

Therapeutic area

Hematology and blood cancers

Leukemia, lymphoma, myeloma, anemia, hemophilia and sickle cell disease. Drugs are placed in areas by keyword matches on their FDA pharmacologic class and approved use, and trials by their listed conditions, so a few land in the wrong area.

Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.govMethods & limitations

Approvals since 2023

31

Originals, plus breakthrough or accelerated new uses

Recruiting Phase 2

285

Industry-sponsored

Recruiting Phase 3

154

Industry-sponsored

Recruiting Phase 4 (post-approval)

19

Industry-sponsored

Recent approvals

All
  • Mimrylo (Rusfertide Acetate) · Takeda Pharms Am NovelPriority reviewOrphanAug 28, 2026

    To treat erythrocytosis in adults with polycythemia vera

  • Zenbexus (Iberdomide Hydrochloride) · Bristol Myers Squibb NovelPriority reviewOrphanAug 13, 2026

    To be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent

  • Sarclisa Escena (Isatuximab-Irfc) · Sanofi-Aventis U.S. LLC OrphanJul 9, 2026
  • Beqalzi (Sonrotoclax) · Beone Medicines USA NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanMay 13, 2026

    To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor

  • Tecvayli (Teclistamab-Cqyv) · Janssen Biotech Breakthrough therapyPriority reviewOrphanMar 5, 2026
  • Epkinly (Epcoritamab-Bysp) · Genmab US, Inc. Breakthrough therapyPriority reviewOrphanNov 18, 2025
  • Komzifti (Ziftomenib) · Kura NovelBreakthrough therapyPriority reviewOrphanNov 13, 2025

    To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options

  • Gazyva (Obinutuzumab) · Genentech Breakthrough therapyOct 17, 2025
  • Wayrilz (Rilzabrutinib) · Genzyme Corp NovelOrphanAug 29, 2025

    To treat persistent or chronic immune thrombocytopenia that has not sufficiently responded to immunoglobulins, anti-D therapy, or corticosteroids

  • Lynozyfic (Linvoseltamab-Gcpt) · Rengeneron Pharmaceuticals, Inc. NovelAccelerated approvalPriority reviewOrphanJul 2, 2025

    To treat relapsed or refractory multiple myeloma after at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti CD38 monoclonal antibody

  • Uplizna (Inebilizumab-Cdon) · Viela Bio Breakthrough therapyPriority reviewOrphanApr 3, 2025
  • Qfitlia (Fitusiran Sodium) · Genzyme Corp NovelOrphanMar 28, 2025

    To prevent or reduce the frequency of bleeding episodes in hemophilia A or B

  • Grafapex (Treosulfan) · Medexus NovelOrphanJan 21, 2025

    For use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome

  • Alhemo (Concizumab-Mtci) · Novo Nordisk INC NovelPriority reviewOrphanDec 20, 2024

    For routine prophylaxis to prevent bleeding episodes in hemophilia A and B

  • Revuforj (Revumenib Citrate) · Syndax NovelBreakthrough therapyPriority reviewOrphanNov 15, 2024

    To treat relapsed or refractory acute leukemia

Recruiting trials by phase

Industry-sponsored drug and biologic trials.

Most approvals since then, by company

Drugs in development

Investigational drugs in Phase 2 and 3 trials for conditions in this area, most trials first.

All
  • SintilimabIBI308Phase 321 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma

  • AdabelimumabSHR-A2102, SHR2554Phase 320 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma

  • IanalumabVAY736, VAY736 AIPhase 318 trials

    Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome

  • AK117Phase 314 trials

    Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes

  • OrelabrutinibICP-022Phase 311 trials

    Beijing InnoCare Pharma Tech Co., Ltd. · Mantle Cell Lymphoma, Part 1:r/r B-cell Malignancies, Part 2:B-cell Malignancies

  • ZG005Phase 311 trials

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer

  • APG-2575lisaftoclaxPhase 310 trials

    Ascentage Pharma Group Inc. · CLL/SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

  • AZD0120GC012FPhase 39 trials

    AstraZeneca · Newly Diagnosed Multiple Myeloma (NDMM), Relapsed AL Amyloidosis, Refractory AL Amyloidosis

  • FavezelimabMK-4280, MK-4820APhase 39 trials

    Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors

  • MK-2140Zilovertamab Vedotin, VLS-101Phase 39 trials

    Merck & Co. · Diffuse Large B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, B-cell Acute Lymphoblastic Leukemia

  • SurovatamigAZD0486, TNB-486Phase 39 trials

    AstraZeneca · B-cell Non-Hodgkin Lymphoma, Large B-cell Lymphoma, Untreated Follicular Lymphoma

  • TucidinostatChidamide, HBI-8000Phase 39 trials

    Chipscreen Biosciences, Ltd. · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Unresectable or Metastatic Melanoma, Progressive Brain Metastasis

  • EtentamigABBV-383, TNB-383BPhase 38 trials

    AbbVie · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Amyloid Light Chain (AL) Amyloidosis

  • BirelentinibDZD8586Phase 37 trials

    Dizal Pharmaceuticals · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, Immune Thrombocytopenia (ITP)

  • BMS-986348CC-92480, mezigdomidePhase 37 trials

    Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma

Largest recruiting Phase 3 trials

All

More: Hematology and blood cancers news · literature

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.